icon
An official government website affiliated with the Government of the Kingdom of Saudi Arabia.
icon Tue 17 Nov 2026
Beta version
icon
Official Saudi government website domains end with gov.sa

All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.

icon
Official Reliable websites use HTTPS

Ensure the website is using the HTTPS protocol.

icon

Registered with the Digital Government Authority under number:

20250831619
Suggestions

SFDA Signs Memorandum of Understanding with the UK’s MHRA to Support Innovation and Accelerate Patient Access to Treatments

Food
Drugs
Medical Devices
Cosmetics

SFDA Signs Memorandum of Understanding with the UK’s MHRA to Support Innovation and Accelerate Patient Access to Treatments

icon

The Saudi Food and Drug Authority (SFDA) has signed a Memorandum of Understanding (MoU) with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) to enhance the evaluation of innovative therapies and facilitate timely patient access while maintaining high standards of safety, quality, and efficacy. The signing took place on the sidelines of the DIA–MHRA Global Summit, held in London on November 16–17, 2026.

The MoU was signed by the CEO of the SFDA, H.E. Dr. Hisham S. Aljadhey, and the Chief Executive of the MHRA, Mr. Lawrence Tallon, in the presence of MHRA Chair Mr. Anthony Harnden. Following the signing, the two sides held a bilateral meeting to discuss cooperation priorities in light of the latest scientific and regulatory developments.

Building on existing collaboration and a shared commitment to keeping pace with medical innovation, the MoU covers the assessment of rare disease treatments, advanced therapies, and biotechnology products. It also includes the exchange of knowledge on the application of artificial intelligence, modeling, and computer simulation in clinical studies and trials. This cooperation helps provide developers with greater clarity on regulatory requirements early in the development process, particularly when developing treatments for patients with limited therapeutic options.

Under the MoU, SFDA and MHRA will exchange information and expertise in medical product registration and assessment, Good Manufacturing Practices (GMP), quality management systems, product testing and analysis, and supply chain monitoring. Together, these efforts support the safety of medical products in Saudi and UK markets and strengthen both sides to identify and mitigate associated risks.

This cooperation supports Saudi Vision 2030 goals to improve quality of life by facilitating patient access to safe and effective treatments. It also aligns with the National Biotechnology Strategy’s focus on developing national capabilities and fostering sector innovation through scientific exchange and advanced regulatory assessment methods for biological medicines and innovative therapies.

DSC_6918.jpg.jpeg
DSC_6944.jpg.jpeg
DSC_7116.jpg.jpeg